| Document and Entity Information | 6 Months Ended |
| Jun. 30, 2024 | |
| Cover [Abstract] | |
| Entity Registrant Name | MediWound Ltd. |
| Entity Central Index Key | 0001593984 |
| Document Type | 6-K |
| Document Period End Date | Jun. 30, 2024 |
| Amendment Flag | false |
| Current Fiscal Year End Date | --12-31 |
| Document Fiscal Period Focus | Q2 |
| Document Fiscal Year Focus | 2023 |
| Entity File Number | 001-36349 |
| Entity Address, Address Line One | 42 Hayarkon Street |
| Entity Address, City or Town | Yavne |
| Entity Address, Postal Zip Code | 8122745 |
| Entity Address, Country | IL |
| Unaudited Condensed Interim Consolidated Statements of Financial Position - USD ($) $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 | Jun. 30, 2023 | ||
| CURRENT ASSETS: | |||||
| Cash and cash equivalents | $ 3,790 | $ 11,866 | $ 19,166 | ||
| Short-term and restricted bank deposits | 25,425 | 29,842 | 31,956 | ||
| Trade receivables | 2,922 | 3,700 | 3,228 | ||
| Inventories | 3,210 | 2,846 | 3,113 | ||
| Other receivables | 1,966 | 1,441 | 590 | ||
| Total current assets | 37,313 | 49,695 | 58,053 | ||
| LONG-TERM ASSETS: | |||||
| Other receivables | 238 | 233 | 277 | ||
| Long-term restricted bank deposits | 453 | 440 | 0 | ||
| Property, plant and equipment, net | 12,308 | 9,228 | 4,705 | ||
| Right-of-use assets, net | 6,852 | 6,698 | 1,133 | ||
| Intangible assets, net | 132 | 165 | 198 | ||
| Total non-current assets | 19,983 | 16,764 | 6,313 | ||
| Total assets | 57,296 | 66,459 | 64,366 | ||
| CURRENT LIABILITIES: | |||||
| Current maturities of long-term liabilities | 1,496 | 1,410 | 1,961 | ||
| Warrants, net | 14,902 | 7,296 | [1] | 9,683 | [1] |
| Trade payables and accrued expenses | 2,745 | 5,528 | 3,531 | ||
| Other payables | 3,468 | 3,891 | 2,817 | ||
| Total current liabilities | 22,611 | 18,125 | 17,992 | ||
| LONG-TERM LIABILITIES: | |||||
| Liabilities in respect of IIA grants | 8,009 | 7,677 | 7,806 | ||
| Liabilities in respect of TEVA | 1,962 | 2,256 | 2,529 | ||
| Lease liabilities | 6,355 | 6,350 | 677 | ||
| Severance pay liability, net | 490 | 456 | 433 | ||
| Total non-current liabilities | 16,816 | 16,739 | 11,445 | ||
| Total liabilities | 39,427 | 34,864 | 29,437 | ||
| Shareholders' equity: | |||||
| Ordinary shares of NIS 0.07 par value: Authorized: 20,000,000 shares as of June 30, 2024 and December 31, 2023; 12,857,143 as of June 30, 2023; Issued and Outstanding: 9,286,252 as of June 30, 2024; 9,221,764 as of December 31, 2023 and 9,216,520 as of June 30, 2023 | 186 | 184 | 184 | ||
| Share premium | 208,547 | 206,251 | 205,642 | ||
| Foreign currency translation adjustments | (8) | (18) | (14) | ||
| Accumulated deficit | (190,856) | (174,822) | (170,883) | ||
| Total equity | 17,869 | 31,595 | 34,929 | ||
| Total liabilities and equity | $ 57,296 | $ 66,459 | $ 64,366 | ||
| [1]Reclassified, see note 2c | |||||
| Unaudited Condensed Interim Consolidated Statements of Financial Position (Parenthetical) - ₪ / shares | Jun. 30, 2024 | Dec. 31, 2023 | Jun. 30, 2023 |
| Statement of financial position [abstract] | |||
| Ordinary shares, par value (per share) | ₪ 0.07 | ₪ 0.07 | |
| Number of shares authorised | 20,000,000 | 20,000,000 | 12,857,143 |
| Number of shares issued | 9,286,252 | 9,221,764 | 9,216,520 |
| Number of shares outstanding | 9,286,252 | 9,221,764 | 9,216,520 |
| Unaudited Condensed Interim Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
| Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
| Profit or loss [abstract] | |||||
| Revenues from sale of products | $ 1,506 | $ 1,206 | $ 3,202 | $ 2,358 | $ 6,261 |
| Revenues from development services | 3,504 | 3,534 | 6,727 | 6,149 | 12,265 |
| Revenues from license agreements and royalties | 53 | 33 | 98 | 65 | 160 |
| Total revenues | 5,063 | 4,773 | 10,027 | 8,572 | 18,686 |
| Cost of revenues from sale of products | 1,558 | 628 | 3,144 | 1,436 | 4,927 |
| Cost of revenues from development services | 3,055 | 3,005 | 5,821 | 5,170 | 10,177 |
| Cost of revenues from license agreements and royalties | 3 | 3 | 8 | 3 | 4 |
| Total cost of revenues | 4,616 | 3,636 | 8,973 | 6,609 | 15,108 |
| Gross profit | 447 | 1,137 | 1,054 | 1,963 | 3,578 |
| Research and development | 1,898 | 2,024 | 3,368 | 4,126 | 7,467 |
| Selling and marketing | 1,224 | 1,332 | 2,403 | 2,438 | 4,844 |
| General and administrative | 1,809 | 1,788 | 3,501 | 3,770 | 6,768 |
| Other income | 0 | 0 | 0 | 0 | (211) |
| Total operating expenses | 4,931 | 5,144 | 9,272 | 10,334 | 18,868 |
| Operating loss | (4,484) | (4,007) | (8,218) | (8,371) | (15,290) |
| Financial income | 582 | 5,828 | 1,171 | 7,480 | 10,651 |
| Financial expenses | (2,405) | (893) | (8,965) | (1,869) | (1,892) |
| Financing income (expenses), net | (1,823) | 4,935 | (7,794) | 5,611 | 8,759 |
| Profit (loss) before taxes on income | (6,307) | 928 | (16,012) | (2,760) | (6,531) |
| Taxes on income | 2 | (12) | (22) | (17) | (185) |
| Net profit (loss) | (6,305) | 916 | (16,034) | (2,777) | (6,716) |
| Other comprehensive income (loss): | |||||
| Foreign currency translation adjustments | 2 | 0 | 10 | (9) | (13) |
| Total comprehensive profit (loss) | $ (6,303) | $ 916 | $ (16,024) | $ (2,786) | $ (6,729) |
| Profit (loss) per share data: | |||||
| Basic net profit (loss) per share - USD | $ (0.68) | $ 0.1 | $ (1.73) | $ (0.32) | $ (0.75) |
| Diluted net profit (loss) per share - USD | $ (0.68) | $ 0.1 | $ (1.73) | $ (0.32) | $ (0.75) |
| Number of shares used in calculating basic profit (loss) per share | 9,279,370 | 9,208,902 | 9,256,862 | 8,803,065 | 9,013,144 |
| Number of shares used in calculating diluted profit (loss) per share | 9,279,370 | 9,208,902 | 9,256,862 | 8,803,065 | 9,013,144 |
| Unaudited Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($) $ in Thousands | Share capital [Member] | Share premium [Member] | Foreign currency translation reserve [Member] | Accumulated deficit [Member] | Total |
| Balance at Dec. 31, 2022 | $ 143 | $ 178,882 | $ (5) | $ (168,106) | $ 10,914 |
| Profit (loss) for the period | 0 | 0 | 0 | (2,777) | (2,777) |
| Other comprehensive income (loss) | 0 | 0 | (9) | 0 | (9) |
| Total comprehensive income (loss) | 0 | 0 | (9) | (2,777) | (2,786) |
| Issuance of ordinary shares, net of issuance expenses | 40 | 25,429 | 0 | 0 | 25,469 |
| Exercise of options | 1 | 0 | 0 | 0 | 1 |
| Share-based compensation | 0 | 1,331 | 0 | 0 | 1,331 |
| Balance at Jun. 30, 2023 | 184 | 205,642 | (14) | (170,883) | 34,929 |
| Balance at Dec. 31, 2022 | 143 | 178,882 | (5) | (168,106) | 10,914 |
| Profit (loss) for the period | 0 | 0 | 0 | (6,716) | (6,716) |
| Other comprehensive income (loss) | 0 | 0 | (13) | 0 | (13) |
| Total comprehensive income (loss) | 0 | 0 | (13) | (6,716) | (6,729) |
| Exercise of RSU | 1 | 0 | 0 | 0 | 1 |
| Issuance of ordinary shares, net of issuance expenses | 40 | 25,429 | 0 | 0 | 25,469 |
| Share-based compensation | 0 | 1,940 | 0 | 0 | 1,940 |
| Balance at Dec. 31, 2023 | 184 | 206,251 | (18) | (174,822) | 31,595 |
| Balance at Mar. 31, 2023 | 183 | 204,930 | (14) | (171,799) | 33,300 |
| Profit (loss) for the period | 0 | 0 | 0 | 916 | 916 |
| Other comprehensive income (loss) | 0 | 0 | 0 | 0 | 0 |
| Total comprehensive income (loss) | 0 | 0 | 0 | 916 | 916 |
| Issuance expenses | 0 | 0 | 0 | 0 | 0 |
| Exercise of options | 1 | 0 | 0 | 0 | 1 |
| Share-based compensation | 0 | 712 | 0 | 0 | 712 |
| Balance at Jun. 30, 2023 | 184 | 205,642 | (14) | (170,883) | 34,929 |
| Balance at Dec. 31, 2023 | 184 | 206,251 | (18) | (174,822) | 31,595 |
| Profit (loss) for the period | 0 | 0 | 0 | (16,034) | (16,034) |
| Other comprehensive income (loss) | 0 | 0 | 10 | 0 | 10 |
| Total comprehensive income (loss) | 0 | 0 | 10 | (16,034) | (16,024) |
| Exercise of warrants | 2 | 1,026 | 0 | 0 | 1,028 |
| Share-based compensation | 0 | 1,270 | 0 | 0 | 1,270 |
| Balance at Jun. 30, 2024 | 186 | 208,547 | (8) | (190,856) | 17,869 |
| Balance at Mar. 31, 2024 | 185 | 207,575 | (10) | (184,551) | 23,199 |
| Profit (loss) for the period | 0 | 0 | 0 | (6,305) | (6,305) |
| Other comprehensive income (loss) | 0 | 0 | 2 | 0 | 2 |
| Total comprehensive income (loss) | 0 | 0 | 2 | (6,305) | (6,303) |
| Exercise of warrants | 1 | 214 | 0 | 0 | 215 |
| Share-based compensation | 0 | 758 | 0 | 0 | 758 |
| Balance at Jun. 30, 2024 | $ 186 | $ 208,547 | $ (8) | $ (190,856) | $ 17,869 |
| Unaudited Condensed Interim Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
| Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |||
| Cash flows from operating activities: | |||||||
| Net Profit (loss) | $ (6,305) | $ 916 | $ (16,034) | $ (2,777) | $ (6,716) | ||
| Adjustments to profit and loss items: | |||||||
| Depreciation and amortization | 357 | 315 | 725 | 618 | 1,303 | ||
| Share-based compensation | 758 | 712 | 1,270 | 1,331 | 1,940 | ||
| Revaluation of warrants accounted at fair value | 1,927 | (4,990) | 8,007 | (5,923) | (8,310) | ||
| Revaluation of liabilities in respect of IIA grants | 237 | 233 | 470 | 492 | 427 | ||
| Revaluation of liabilities in respect of TEVA | 99 | 119 | 206 | 241 | 468 | ||
| Financing income and exchange differences of lease liability | (11) | (9) | 17 | (22) | 257 | ||
| Increase in severance pay liability, net | 13 | (10) | 48 | 67 | 83 | ||
| Other income | 0 | 0 | 0 | 0 | (211) | ||
| Financial income, net | (405) | (759) | (918) | (1,005) | (2,231) | ||
| Un-realized foreign currency loss | 11 | 120 | 78 | 466 | 189 | ||
| Adjustments to profit and loss items, total | 2,986 | (4,269) | 9,903 | (3,735) | (6,085) | ||
| Changes in asset and liability items: | |||||||
| Decrease (increase) in trade receivables | 876 | (707) | 753 | 6,115 | 5,658 | ||
| Decrease (increase) in inventories | 103 | (579) | (345) | (1,162) | (906) | ||
| Decrease (increase) in other receivables | (459) | 435 | (574) | 122 | (894) | ||
| Increase (decrease) in trade payables and accrued expenses | (530) | 312 | (1,900) | (1,636) | (594) | ||
| Decrease in other payables | (294) | (1,359) | (34) | (1,526) | (928) | ||
| Changes in asset and liability items, total | (304) | (1,898) | (2,100) | 1,913 | 2,336 | ||
| Net cash used in operating activities | (3,623) | (5,251) | (8,231) | (4,599) | (10,465) | ||
| Cash Flows from Investing Activities: | |||||||
| Purchase of property and equipment | (3,016) | (1,065) | (4,275) | (2,570) | (6,464) | ||
| Interest received | 522 | 577 | 1,127 | 879 | 1,947 | ||
| Proceeds from (investment in) short term bank deposits, net | 5,339 | (25,590) | 4,209 | (31,830) | (29,804) | ||
| Net cash provided by (used in) investing activities | 2,845 | (26,078) | 1,061 | (33,521) | (34,321) | ||
| Cash Flows from Financing Activities: | |||||||
| Repayment of leases liabilities | (214) | (157) | (458) | (334) | (778) | ||
| Proceeds from exercise of warrants | 111 | [1] | 610 | [1] | 0 | ||
| Proceeds from issuance of shares and warrants, net | 0 | (248) | 0 | 24,909 | 24,909 | ||
| Repayment of IIA grants, net | 0 | 0 | (120) | (310) | (380) | ||
| Repayment of liabilities in respect of TEVA | 0 | 0 | (834) | (417) | (834) | ||
| Net cash provided by (used in) financing activities | (103) | (405) | (802) | 23,848 | 22,917 | ||
| Exchange rate differences on cash and cash equivalent balances | (15) | (120) | (104) | (457) | (160) | ||
| Decrease in cash and cash equivalents | (896) | (31,854) | (8,076) | (14,729) | (22,029) | ||
| Balance of cash and cash equivalents at the beginning of the period | 4,686 | 51,020 | 11,866 | 33,895 | 33,895 | ||
| Balance of cash and cash equivalents at the end of the period | 3,790 | 19,166 | 3,790 | 19,166 | 11,866 | ||
| Supplement disclosure of Non-cash transactions: | |||||||
| ROU asset, net recognized with corresponding lease liability | 0 | 102 | 365 | 154 | 6,825 | ||
| Purchase Of Property And Equipment | $ (43) | $ 0 | $ (142) | $ 0 | $ (1,011) | ||
| [1]Represents an amount lower than $1. | |||||||
| General | 6 Months Ended |
| Jun. 30, 2024 | |
| Disclosure Of General Information [Abstract] | |
| General | Note 1: General a. Description of the Company and its operations: MediWound Ltd. Was incorporated in Israel in January 2000. The Company which is located in Yavne, Israel (The "Company" or "MediWound"), is biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic, non-surgical solutions for tissue repair and regeneration. The Company’s strategy leverages its breakthrough enzymatic technology platform into diversified portfolio of biotherapeutics across multiple indications to pioneer solutions for unmet medical needs. The Company’s current portfolio is focused on next-generation protein-based therapies for burn care, wound care and tissue repair. The Company's first innovative biopharmaceutical product, Nexobrid, has received in December 2022, an approval from the U.S. Food and Drug Administration (“FDA”) and marketing approval in each of India, Switzerland and Japan. In addition, it has a marketing authorization from the European Medicines Agency (“EMA”) and regulatory agencies in other international markets for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns. The Company commercialize Nexobrid globally through multiple sales channels. The Company sells Nexobrid to burn centers in the European Union, United Kingdom and Israel, primarily through its commercial organizations. The Company has established local distribution channels in multiple international markets, focusing on Asia Pacific, EMEA, CEE and LATAM, which local distributors are also responsible for obtaining local marketing authorization within the relevant territories. In the United States, the Company entered into an exclusive license and supply agreements with Vericel Corporation (“Vericel”) to commercialize Nexobrid in North America upon FDA approval. On September 21, 2023, the Company announced the U.S. commercial availability of Nexobrid® for the removal of eschar in adults with deep partial- and/or full-thickness thermal burns. On September 20, 2022, The Company announced that EMA has validated for review the Type II Variation to expand the currently approved indication for Nexobrid (removal of eschar in adults with deep partial-and full-thickness thermal burn wounds) into the pediatric population. The Company’s second investigational next-generation enzymatic therapy product, EscharEx, a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds. The Company expected to initiate the Phase III study in the second half of 2024. b. The Company's securities are listed for trading on NASDAQ since March 2014. c. The Company has three wholly owned subsidiaries: MediWound Germany GmbH, acting as Europe (“EU”) marketing authorization holder and EU sales and marketing arm, and MediWound UK Limited and MediWound US, Inc. which are currently inactive companies. d. In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these consolidated financial statements, the war in Israel is ongoing and continues to evolve. The company’s head quarter, manufacturing and R&D facilities are located in Israel. Currently, such activities in Israel remain largely unaffected. During the first half of 2024, the impact of this war on the company’s results of operations and financial condition was immaterial. e. BARDA In September 2015, the Company was awarded BARDA Contract for treatment of thermal burn injuries. This contract was amended multiple times to extend its term until September 2024 and its total value, up to a total amount of $175,000 as of the end of 2023. On May 11 2024 the company signed an extension to the contracts with BARDA until September 2025. As of June 30, 2024, the Company has received approximately $92,065 in total funding from BARDA under the first contract, and an additional $16,500 for procurement of Nexobrid for U.S. emergency preparedness, which were recorded at the net amount of approximately $10,500 following the split of gross profit agreement with Vericel for the initial BARDA procurement. f. DOD and MTEC contracts: On February 17, 2022, the Company was entered into a contract with the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), to develop Nexobrid as a non-surgical solution for field-care burn treatment for the U.S. Army. The contract provides funding up to $2,727. During 2023, the DoD through MTEC awarded the Company additional funding of $9,117 in addition, the company awarded directly through MTEC funding of $1,190, to advance the development of a new temperature stable formulation of Nexobrid. In May 2024 the Company was awarded an additional funding of $1,557 from the DoD through MTEC. The total funding from the DoD and MTEC is $14,591. g. In June 2024, the Company signed new agreements with suppliers to precure services totaling $3,300 for the Phase III clinical trial of EscharEx, covering a period of two years. h. The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern. From inception to June 30, 2024, the Company has incurred cash outflows from operations, losses from operations, and has an accumulated deficit of $190.9 million. The Company believes that its existing cash and cash equivalents, short-term and restricted bank deposits of $29.2 million as of June 30, 2024, will be sufficient to fund its operations and capital expenditure for at least twelve months from the date of issuance of these consolidated financial statements. |
| Material Accounting Policies | 6 Months Ended |
| Jun. 30, 2024 | |
| Disclosure of significant accounting policies [Abstract] | |
| Material Accounting Policies | Note 2: Material Accounting Policies The following accounting policies have been applied consistently in the financial statements for all periods presented unless otherwise stated. a. Basis of presentation of financial statements: These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). b. Basis of preparation of the interim consolidated financial statements: The interim condensed consolidated financial statements for the six and three months ended June 30, 2024, have been prepared in accordance with IAS 34 "Interim Financial Reporting". These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and do not include all of the information required for full annual financial statements. They should be read in conjunction with the financial statements as at and for the year ended December 31, 2023 (hereinafter – “the annual financial statements”). These condensed consolidated interim financial statements were authorized for issue by the Group’s Board of Directors on August 14, 2024. c. Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current (amendment to IAS 1). As a result of applying the Amendment the warrants presented in these financial statements were classified as a current liability pursuant to the conversion option. |
| Equity | 6 Months Ended |
| Jun. 30, 2024 | |
| SHAREHOLDERS' EQUITY: | |
| Equity | Note 3: Equity 1. On February 26, 2024, the Company granted 316,165 share options to employees, officers, board members, CEO and several consultants at an exercise price of $12.73 per share and 30,482 RSUs. The share options and the RSUs vest over a period of 1-4 years. The grants to the directors and CEO were subject to approval at the next annual shareholders' meeting. The grants to the directors and CEO were approved in the annual shareholders' meeting held on July 9 ,2024. 2. During the first half of 2024, 46,456 Series A warrants were exercised to the Company ordinary shares at an exercise price of $13.475 per ordinary share, in accordance with the terms of the Series A warrants. |
| Subsequent events | 6 Months Ended |
| Jun. 30, 2024 | |
| Disclosure of non-adjusting events after reporting period [abstract] | |
| Subsequent events | Note 4: Subsequent events 1. On July 15, 2024, the Company entered into a definitive share purchase agreement. The agreement includes the sale and purchase of 1,453,488 shares of the Company’s ordinary shares, each with a par value NIS 0.07 (the “Ordinary Shares”), in a private investment in public equity (the “PIPE Offering”). The purchase price is set at $17.20 per share. The gross proceeds from the PIPE Offering are $25,000. 2. Concurrently with the PIPE offering, on July 15, 2024, the Company and Teva Pharmaceutical Industries Ltd. (“Teva”) entered into Amendment No. 2 (the “Amendment”) to the settlement agreement and mutual general release, dated March 24, 2019, as previously amended by Amendment No. 1, dated December 13, 2020, by and between the Company and Teva (the “Agreement”). Under the terms of the Amendment, the Company will pay Teva $4,000 as the final payment due from the Company under the Agreement, with 50% of such prepayment in cash and 50% in the form of ordinary shares of the Company to be issued by the Company to Teva (as part of the PIPE offering), all in accordance with the terms and timeframe specified in the Amendment (“The transaction”). As a result of the transaction, the company will record financial expenses of $550 and the liability in respect of TEVA will be settled. 3. On July 16, 2024, 44,573 Series A warrants were exercised to the Company ordinary shares at an exercise price of $13.475 per ordinary share, in accordance with the terms of the Series A warrants. 4. Following the PIPE offering, exercise of Series A warrants, and exercise of options, the Company’s updated number of Issued and Outstanding shares are 10,786,423. 5. On July 16, 2024, the company was selected to receive 16,250 in blended funding from the European Innovation Council (EIC) through its accelerator program. Funding of 2,500 is expected to be received as a grant, and 13,750 as an investment. The terms of the investment are currently being negotiated. 6. In July 2024, the Company signed new agreements with suppliers to procure services totaling $6,086 for the Phase III clinical trial of EscharEx, covering a period of two years. |
| Material Accounting Policies (Policies) | 6 Months Ended |
| Jun. 30, 2024 | |
| Disclosure of significant accounting policies [Abstract] | |
| Basis of presentation of financial statements | a. Basis of presentation of financial statements: These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). |
| Basis of preparation of the interim consolidated financial statements | b. Basis of preparation of the interim consolidated financial statements: The interim condensed consolidated financial statements for the six and three months ended June 30, 2024, have been prepared in accordance with IAS 34 "Interim Financial Reporting". These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and do not include all of the information required for full annual financial statements. They should be read in conjunction with the financial statements as at and for the year ended December 31, 2023 (hereinafter – “the annual financial statements”). These condensed consolidated interim financial statements were authorized for issue by the Group’s Board of Directors on August 14, 2024. |
| Presentation of Financial Statements | c. Presentation of Financial Statements: Classification of Liabilities as Current or Non-Current (amendment to IAS 1). As a result of applying the Amendment the warrants presented in these financial statements were classified as a current liability pursuant to the conversion option. |
| General (Narrative) (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
| Jun. 30, 2024 | Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | May 31, 2024 | Feb. 17, 2022 | |
| Disclosure of associates [line items] | ||||||||
| Gross profit | $ 447 | $ 1,137 | $ 1,054 | $ 1,963 | $ 3,578 | |||
| Accumulated deficit | $ (190,856) | (190,856) | $ (170,883) | (190,856) | $ (170,883) | (174,822) | ||
| Cash and cash equivalents, short-term and restricted bank deposits | 29,200 | 29,200 | 29,200 | |||||
| Suppliers [Member] | ||||||||
| Disclosure of associates [line items] | ||||||||
| Contracts with customers | 3,300 | |||||||
| U.S. Department of Defense (DoD) [Member] | ||||||||
| Disclosure of associates [line items] | ||||||||
| Funding amount | 14,591 | 14,591 | 14,591 | $ 2,727 | ||||
| Additional funding amount | 9,117 | $ 1,557 | ||||||
| Advance funding | 1,190 | |||||||
| BARDA [Member] | ||||||||
| Disclosure of associates [line items] | ||||||||
| Contract amount for research, development and manufacturing | $ 175,000 | |||||||
| Funding amount | 92,065 | 92,065 | 92,065 | |||||
| Additional funding amount | $ 16,500 | $ 16,500 | 16,500 | |||||
| Gross profit | $ 10,500 | |||||||
| Equity (Narrative) (Details) | 6 Months Ended | |
| Feb. 26, 2024 Share $ / shares | Jun. 30, 2024 Share $ / shares | |
| Series A warrants [Member] | ||
| Disclosure of classes of share capital [line items] | ||
| Warrants were exercised | 46,456 | |
| Warrant exercise price | $ / shares | $ 13.475 | |
| Employees, officers, board members, CEO and several consultants [Member] | Share Options [Member] | ||
| Disclosure of classes of share capital [line items] | ||
| Number of options granted | 316,165 | |
| Exercise price per share | $ / shares | $ 12.73 | |
| Vesting period of share options | 1-4 years | |
| Employees, officers, board members, CEO and several consultants [Member] | Restricted Shares Units [Member] | ||
| Disclosure of classes of share capital [line items] | ||
| Number of restricted share units granted | 30,482 | |
| Vesting period of share options | 1-4 years |
| Subsequent events (Narrative) (Details) $ / shares in Units, € in Thousands, $ in Thousands | 1 Months Ended | |||||||
| Jul. 15, 2024 ₪ / shares shares | Jul. 15, 2024 USD ($) | Jul. 31, 2024 USD ($) | Jul. 16, 2024 EUR (€) shares | Jul. 16, 2024 $ / shares | Jun. 30, 2024 ₪ / shares shares | Dec. 31, 2023 ₪ / shares shares | Jun. 30, 2023 shares | |
| Disclosure of non-adjusting events after reporting period [line items] | ||||||||
| Number of shares issued | 9,286,252 | 9,221,764 | 9,216,520 | |||||
| Number of shares outstanding | 9,286,252 | 9,221,764 | 9,216,520 | |||||
| Par value per share | ₪ / shares | ₪ 0.07 | ₪ 0.07 | ||||||
| Subsequents Event [Member] | ||||||||
| Disclosure of non-adjusting events after reporting period [line items] | ||||||||
| Number of shares issued | 10,786,423 | |||||||
| Number of shares outstanding | 10,786,423 | |||||||
| Number of warrants exercised | 44,573 | |||||||
| Exercise price of warrants | $ / shares | $ 13.475 | |||||||
| Amount of blended funding from European innovation council | € | € 16,250 | |||||||
| Expected funding amount received as grant | € | 2,500 | |||||||
| Investment amount in property | € | € 13,750 | |||||||
| Subsequents Event [Member] | Suppliers [Member] | ||||||||
| Disclosure of non-adjusting events after reporting period [line items] | ||||||||
| Contracts with customers | $ | $ 6,086 | |||||||
| Terms of contract | 2 years | |||||||
| Subsequents Event [Member] | Share Purchase Agreement [Member] | ||||||||
| Disclosure of non-adjusting events after reporting period [line items] | ||||||||
| Number of shares issued | 1,453,488 | |||||||
| Par value per share | ₪ / shares | ₪ 0.07 | |||||||
| Purchase price per share | ₪ / shares | ₪ 17.2 | |||||||
| Gross proceeds from the PIPE Offering | $ | $ 25,000 | |||||||
| Subsequents Event [Member] | Teva Pharmaceutical Industries Ltd [Member] | ||||||||
| Disclosure of non-adjusting events after reporting period [line items] | ||||||||
| Amount of final payment | $ | 4,000 | |||||||
| Financial expenses | $ | $ 550 | |||||||
